GlassScriptPhysician profile
Lilliam Miranda
NPI 1710975966
$8,078.47
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,944 · 2020: $1,746 · 2021: $1,447 · 2022: $1,391 · 2023: $1,413 · 2024: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529 · Education: $22.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.72 |
| Education | $22.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,223.58 | 2019-2024 | |
| Amgen INC. | $775.99 | 2019-2023 | Enbrel, Tavneos |
| Janssen Biotech, INC. | $709.02 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Horizon Therapeutics Plc | $611.87 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $607.58 | 2019-2023 | |
| Glaxosmithkline, LLC. | $504.38 | 2019-2024 | Benlysta |
| Ucb, INC. | $471.25 | 2019-2023 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $350.02 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $347.05 | 2020-2023 | Acthar |
| Aurinia Pharma U.S., INC. | $345.46 | 2021-2023 | Lupkynis |
| Radius Health, INC. | $302.83 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.38 | 2020-2024 | Ofev |
| Pfizer INC. | $200.45 | 2019-2022 | |
| Lilly USA, LLC | $199.04 | 2019-2023 | Taltz |
| Sanofi-Aventis U.S. LLC | $164.25 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $161.88 | 2022-2023 | Saphnelo |
| Ani Pharmaceuticals, INC. | $130.11 | 2023 | Purified Cortrophin Gel |
| Sobi, INC | $95.20 | 2019-2020 | |
| Genzyme Corporation | $90.93 | 2019-2020 | |
| Celgene Corporation | $56.26 | 2019 | |
| Medexus Pharma, INC. | $55.79 | 2019-2020 | |
| Pacira Therapeutics, INC. | $55.37 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $50.88 | 2019 | |
| Organon LLC | $40.46 | 2021-2023 | Hadlima |
| Cumberland Pharmaceuticals, INC. | $38.77 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $34.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $34.02 | 2020 | |
| Octapharma USA, INC. | $31.93 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $26.44 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $25.79 | 2024 | Iovera, Zilretta |
| Alexion Pharmaceuticals, INC. | $24.38 | 2020 | |
| Alvogen INC | $23.67 | 2022 | |
| Hikma Pharmaceuticals USA | $22.41 | 2019 | |
| Celltrion USA INC. | $22.33 | 2023 | Yuflyma |
| Ultragenyx Pharmaceutical INC. | $21.69 | 2021 | |
| Antares Pharma, INC. | $16.10 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilliam Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.